What’s Oramed Pharmaceuticals Inc. (ORMP) Downside After Achieving 1 Year Low?

July 16, 2018 - By Pearl Odom

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Logo

Investors sentiment decreased to 0.33 in 2018 Q1. Its down 2.42, from 2.75 in 2017Q4. It fall, as 5 investors sold Oramed Pharmaceuticals Inc. shares while 4 reduced holdings. 2 funds opened positions while 1 raised stakes. 234,885 shares or 28.63% less from 329,110 shares in 2017Q4 were reported.
Glenmede Trust Na has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). 24,919 are held by Deutsche National Bank Ag. Wells Fargo Mn holds 8,100 shares or 0% of its portfolio. Moreover, Barclays Pcl has 0% invested in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 41,186 shares. Bancorp Of Montreal Can stated it has 2,600 shares. Royal Natl Bank Of Canada reported 1,500 shares. Pnc Financial Grp Incorporated has 0% invested in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Citigroup, a New York-based fund reported 6,545 shares. Jfs Wealth Ltd stated it has 0% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Morgan Stanley reported 33,887 shares or 0% of all its holdings. Fin Architects accumulated 2,750 shares. Renaissance Tech Limited Com holds 0% or 69,800 shares. New York-based Tower Research Capital (Trc) has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). 1,117 were reported by National Bank & Trust Of America De.

Since July 10, 2018, it had 1 buying transaction, and 0 insider sales for $357 activity.

The stock of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) hit a new 52-week low and has $5.40 target or 4.00 % below today’s $5.63 share price. The 5 months bearish chart indicates high risk for the $97.75M company. The 1-year low was reported on Jul, 16 by Barchart.com. If the $5.40 price target is reached, the company will be worth $3.91 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 5.85% or $0.3501 during the last trading session, reaching $5.6299. About 54,019 shares traded or 77.47% up from the average. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has declined 10.31% since July 16, 2017 and is downtrending. It has underperformed by 22.88% the S&P500.

More notable recent Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) news were published by: Streetinsider.com which released: “Oramed Pharma (ORMP) Announces 2.89M Unit Registered Direct Offering at $6.25/Unit” on July 03, 2018, also Benzinga.com with their article: “Mid-Day Market Update: US Stocks Turn Negative; Anavex Life Sciences Shares Spike Higher” published on July 03, 2018, Prnewswire.com published: “Oramed Announces Closing of $18.1 Million Registered Direct Offering” on July 07, 2018. More interesting news about Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares” published on July 11, 2018 as well as Prnewswire.com‘s news article titled: “Oramed to be Added to Russell Microcap® Index” with publication date: June 19, 2018.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company has market cap of $97.75 million. The Company’s product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. It currently has negative earnings. The firm operates primarily in Israel.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.